 Mustang Bio, Inc. Mustang MBIO, a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the first subject treated with the optimized MB-106 CD20-targeted, autologous CAR T cell therapy manufacturing process, developed in collaboration between Mustang and Fred Hutchinson Cancer Research Center Fred Hutch, has achieved a complete response CR at the lowest starting dose in an ongoing Phase 12 clinical trial. The trial is evaluating the safety and efficacy of MB-106 in subjects with relapsed or refractory B-cell non-Hodgkin lymphomas. 